Hemostemix Inc. Stock Analysis HEM.V

Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The company is headquartered in Calgary, Alberta. The company went IPO on 2012-12-20. The firm has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). The company holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company has completed a Phase II clinical trial for chronic limb-threatening ischemia. The company has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.